SEC Comment Letter 0000000000-24-003386 to Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc.
Date: March 29, 2024 · CIK: 0001671584 · Accession: 0000000000-24-003386
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278103
Letter
United States securities and exchange commission logo March 29, 2024 Marvin White Chief Executive Officer Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, WA 98121 Re:Aptevo Therapeutics Inc. Registration Statement on Form S-1 Filed March 20, 2024 File No. 333-278103 Dear Marvin White: We have conducted a limited review of your registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Registration Statement on Form S-1 Cover Page 1.We note your disclosure on page 23 that this offering will terminate no later than April 20, 2024, unless you decide to terminate the offering prior to that date. Please revise your cover page to disclose this date, rather than stating that the offer will terminate "no later than three trading days from the date of this prospectus". See Item 501(b)(8)(iii) of Regulation S-K. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.
FirstName LastNameMarvin White Comapany NameAptevo Therapeutics Inc. March 29, 2024 Page 2 FirstName LastName Marvin White Aptevo Therapeutics Inc. March 29, 2024 Page 2 Please contact Doris Stacey Gama at 202-551-3188 or Laura Crotty at 202-551-7614 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sean Donahue, Esq.
Show Raw Text
United States securities and exchange commission logo
March 29, 2024
Marvin White
Chief Executive Officer
Aptevo Therapeutics Inc.
2401 4th Avenue, Suite 1050
Seattle, WA 98121
Re:Aptevo Therapeutics Inc.
Registration Statement on Form S-1
Filed March 20, 2024
File No. 333-278103
Dear Marvin White:
We have conducted a limited review of your registration statement and have the
following comment.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Registration Statement on Form S-1
Cover Page
1.We note your disclosure on page 23 that this offering will terminate no later than April 20,
2024, unless you decide to terminate the offering prior to that date. Please revise your
cover page to disclose this date, rather than stating that the offer will terminate "no later
than three trading days from the date of this prospectus". See Item 501(b)(8)(iii) of
Regulation S-K.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
FirstName LastNameMarvin White
Comapany NameAptevo Therapeutics Inc.
March 29, 2024 Page 2
FirstName LastName
Marvin White
Aptevo Therapeutics Inc.
March 29, 2024
Page 2
Please contact Doris Stacey Gama at 202-551-3188 or Laura Crotty at 202-551-7614 with
any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Sean Donahue, Esq.